2 recruiting, 1 enrolling by invitation. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 2 |
| Phase 2 | 1 | Enrolling by invitation 1 |
Follow NeuShen Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I Study of NS-079 in Healthy Participants Placebo, NS-079 tablet, Paroxetine - Healthy Adult Participants | Phase 1 | Recruiting | NeuShen Therapeutics | 78 | 2026-07-30 | 2026-09-15 |
| A Phase II Clinical Study to Evaluate the Efficacy and Safety of NS-136 in the Treatment of Schizophrenia NS-136 - Schizophrenia(Acute) | Phase 2 | Enrolling by invitation | NeuShen Therapeutics | 150 | 2025-10-20 | 2026-04-13 |
| First-into-human Study of NS-136 in Healthy Subjects Placebo, NS-136 tablet - Healthy Subjects | Phase 1 | Recruiting | NeuShen Therapeutics | 76 | 2024-04-30 | 2024-11-19 |
Paroxetine (1)
Australia (2) · China (2)
Emir Redzepagic, MD (1) · Xiaolan Yong Chief Pharmacist, BS (1)